External Source:
Diabetes & TB | Lancet Diabetes & Endocrinology | Volume 2, pp. 740-753

“Diabetes increases the risk of developing active tuberculosis and is associated with worse tuberculosis treatment outcomes. Globally, 15% of tuberculosis cases are estimated to be attributable to diabetes […] Diabetes will make an increasingly important contribution to the tuberculosis epidemic. Whether screening for diabetes in patients with tuberculosis (and the converse) is feasible and cost-effective, and how those identified with concurrent tuberculosis and diabetes can be best managed, are key research questions.”

Abstract

Diabetes triples the risk for active tuberculosis, thus the increasing burden of type 2 diabetes will help to sustain the present tuberculosis epidemic. Recommendations have been made for bidirectional screening, but evidence is scarce about the performance of specific tuberculosis tests in individuals with diabetes, specific diabetes tests in patients with tuberculosis, and screening and preventive therapy for latent tuberculosis infections in individuals with diabetes. Clinical management of patients with both diseases can be difficult. Tuberculosis patients with diabetes have a lower concentration of tuberculosis drugs and a higher risk of drug toxicity than tuberculosis patients without diabetes. Good glycaemic control, which reduces long-term diabetes complications and could also improve tuberculosis treatment outcomes, is hampered by chronic inflammation, drug-drug interactions, suboptimum adherence to drug treatments, and other factors. Besides drug treatments for tuberculosis and diabetes, other interventions, such as education, intensive monitoring, and lifestyle interventions, might be needed, especially for patients with newly diagnosed diabetes or those who need insulin. From a health systems point of view, delivery of optimum care and integration of services for tuberculosis and diabetes is a huge challenge in many countries. Experience from the combined tuberculosis and HIV/AIDS epidemic could serve as an example, but more studies are needed that include economic assessments of recommended screening and systems to manage concurrent tuberculosis and diabetes.